retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial Eli Lilly's shows promising weight loss results in 3 Retatrutide's mechanisms of action. |
Description
2021 Jul 17;398(10296):212 )
2025;57 doi: 10.1016/j.ijcha.2025.101638
10 GLP-1, a peptide hormone, is generated by enteroendocrine cells at low baseline levels and by neurons in the caudal medulla
Giacosa A, Guido D, Grassi M, et al
Studies in knock-out mice confirmed the biological action of [dA(2)]GLP-1/GcG which is related to its ability to target GIP, GLP-1, and glucagon receptors
However, changes in the reproductive axis and ovarian morphology were not consistent across all endpoints, and gastrointestinal adverse events were common (96, 97)
00967-0/asset/1cda1e69-507e-47d1-ad73-620bcd1cbb66/main.assets/gr2_lrg.jpg)
